Table 4 Current ongoing early phase I/II trials with ALK inhibitors in advanced NSCLC
From: Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
ALK inhibitors | ||||
|---|---|---|---|---|
Drug name | Mechanism of action | Clinical trial (Phase) | Study design | Disease |
Alectinib | ALK inhibitor | NCT03202940 (1/2) | Combination with Cobimetinib | Advanced ALK rearranged NSCLC with progression on Alectinib |
Brigatinib | Dual ALK and EGFR inhibitor | NCT02706626 (2) | Monotherapy | Advanced ALK rearranged NSCLC with progression on ALK inhibitors |
Brigatinib | Dual ALK and EGFR inhibitor | NCT04227028 (1) | Combination with Bevacizumab | Advanced ALK rearranged NSCLC with progression on ALK inhibitors |
Ensartinib | Selective ALK inhibitor | NCT04415320 (2) | Monotherapy | Advanced ALK rearranged NSCLC |
TPX-0131 | ALK inhibitor | NCT04849273 (1/2) | Monotherapy | Advanced ALK rearranged NSCLC with progression on at least one prior 2nd or 3rd gen ALK TKI |
TQ-B3139 | Multi-target inhibitor of MET/ALK/ROS | NCT04056572 (2) | Monotherapy | Advanced ALK rearranged NSCLC with progressive disease on Crizotinib |